NIANG Derong 1 , XU Nan 1 , MIAO Jia 1 , QIU Dungong 2 , WEN CongHn 3
  • 1. Institute of Clinical Pharmacology; West China Hospital; Sichuan University2. The Sichuan Provincial Hospital 3. The ThirdPeople’s Hospital of Chengdu; Chengdu 610041;
Amoxicillin/sulbactam; arnpicillin/sulbactam; acute bacterial infections; randomized controlled clinical trial
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective 　To evaluate the efficacy and safety of amoxicillin/sulbactam (AMX/SBT) in the treatment of acute bacterial infections.
Method 　A multicentre randomized controlled clinical trial was conducted. Ampicillin/sulbactam (AMP/SBT) was chosen as the control drug. 113 patients were enrolled in the study (58 cases in test group and 55 cases in control group). AMX/SUL and AMP/SUL were administered 4.5-6.0 g and 4.5-12.0 g every day respectively. Both drugs were given intravenously for 7-14 days.
Results 　The cure rates and the efficacy rates of the two groups were 75.86%, 80.0% and 94.83%, 98.18% respectively. The β-lactamase producing rates were 67.35% , 69.57% and the bacterial clearance rates were 93.88%, 95.65%.There were no significant differences of the above results between the two groups (P gt;0.05). There was no serious adverse drug reaction in AMX/SBT groups.
Conclusion 　This study suggests that AMX/SBT is an effective and safe drug for treating acute bacterial infections.

Citation： NIANG Derong,XU Nan,MIAO Jia,QIU Dungong,WEN CongHn. A multicentre randomized controlled clinical trial on amoxicillin/sulbactam in the treatment of acute bacterial infections. Chinese Journal of Evidence-Based Medicine, 2001, 01(4): 209-217. doi: Copy